The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: A systematic review and meta-analysis

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Tan, Youwen ^a,b   Ding, Keqin ^a   Su, Jing ^a   Trinh, Xuan ^c   Peng, Zhihang ^a   Gong, Yuhua ^b   Chen, Li ^b   Cui, Qian ^a   Lei, Na ^a   Chen, Xin ^a   Yu, Rongbin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b The Third People's Hospital of Zhenjiang Affiliated Jiangsu University   (China)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTIC ACID; DNA POLYMERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHIONINE; TYROSINE; VIRUS DNA; DNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS PROTEIN;

AGE; DISEASE COURSE; GENE DOSAGE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; INFECTION; MEDICAL LITERATURE; META ANALYSIS; PROTEIN MOTIF; REVIEW; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC REVIEW; ANTIVIRAL RESISTANCE; GENETICS; MUTATION; VIROLOGY;

HEPATITIS B VIRUS;

AMINO ACID MOTIFS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL PROTEINS;

EID: 84858981525     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032789     Document Type: Review

References (55)

1. Kao JH, Chen DS, (2002) Global control of hepatitis B virus infection. Lancet Infect Dis 2: 395-403.
2. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, et al. (1996) Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24: 714-717.
3. Tsubota A, (2006) How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection? J Gastroenterol Hepatol 21: 1783-1788.
4. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, et al. (1998) Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27: 1670-1677.
5. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, et al. (2001) Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33: 751-757.
6. Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P, (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Plos Medicine 6.
7. Xiang T, Liu X, Zhang LS, Dai WA, Li ZQ, et al. (2010) The detection of YMDD mutation in CHB patients in Enshi Autonomous Prefecture. Journal of Hubei University for Nationalities 27: 47-49.
8. Wei J, Wang H, Li SL, Zeng LL, (2010) Experimental research for YMDD motif natural mutations in the serum of patients with chronic hepatitis B. Chinese Journal of Hepatology 18: 855-856.
9. Tang XL, (2009) Detection of spontaneous hepatitis B virus YMDD motif mutation by fluorescent hybridization double-probe PCR and melting curve assay. Chinese Journal of Modern Medicine 19: 1544-1546.
10. Shi M, Yang ZJ, Wang RS, Zhang H, Zhu YF, et al. (2006) Rapid quantitation of lamivudine-resistant mutants in lamivudine treated and untreated patients with chronic hepatitis B virus infection. Clin Chim Acta 373: 172-175.
11. Qi QS, Cheng SB, Yang Q, Yi DY, (2005) Study on the therapeutic efficacy of lamivudine in chronic hepatitis B patients with YMDD mutations. Acta Academiae Medicine Jiangxi 45: 42-49.
12. Xiong Y, Song YG, (2005) Detection of YMDD mutants in patients with chronic hepatitis B during lamivudine treatment. Journal of Beihua University 6: 421-424.
13. Ren YQ, Hu DR, Fan GR, Wu YP, (2004) Detection of YMDD mutation in CHB patients untreated with antiviral medicine. Journal of Clinical Hepatology 7: 83-85.
14. Wu C, Ren LY, Li Q, (2007) Detection and analysis of HBV YMDD-motif mutants before and during lamivudine treatment. Medical Laboratory Science and Clinics 18: 46-48.
15. Wang JF, Zhang ZQ, Du MH, Gao T, Gu SM, (2003) Detection of hepatitis B virus YMDD mutants and its clinical significance in patients with chronic hepatitis B. World Journal of infection 3: 405-406.
16. Min XC, Miao XH, Zhao SM, Zhao KK, Yang DG, (2009) The spontaneous YMDD mutation rate in chronic hepatitis B patients. Chinese Journal of Hepatology 17: 887-890.
17. Huo H, Zhao SM, Cai X, Miu XH, (2006) Epidemiological survey of spontaneous HBV YMDD motif mutation. Chinese Hepatology 11: 232-234.
18. Yu HZ, Yuan JF, Zhang XJ, Cheng Y, (2009) Detection of YMDD mutation in patients with hepatitis B by double probe FQ-PCR assay. Medical Information 1: 19-20.
19. Qian JB, Sun NX, Du SC, Fan XF, Zhang YX, (2002) Detection of YMDD motif mutation in lamivudine-treated and untreated CHB patients. Journal of Jiangsu Medicine 28: 408-410.
20. Qiu YW, Huang LH, Hu TH, Cheng SB, Yan Q, (2008) Study of the disease progress and clinical treatment in the hepatitis B patients with YMDD mutation. Clinical Focus 23: 350-352.
21. Chen NL, Zhao SL, Liu XB, Wei YF, Wu HY, et al. (2008) Relationship of YMDD mutations and genotypes of HBV in antivirus-untreated patients with chronic hepatitis B. Chinese Journal of Clinical Physician 2: 1123-1127.
22. Zhang JM, (2004) Clinical analysis on YMDD-motif spontaneous mutation in patients with chronic hepatitis B. Journal of Shangdong Medicine 44: 22-23.
23. Zheng JM, Ni PH, (2003) Detection of YMDD mutation in HBV polymerase gene region with nested PCR. Shanghai Journal of Medical Laboratorial Science 18: 261-264.
24. Cheng FJ, Cheng SL, Lu J, Pang WY, (2006) Analysis of YMDD mutation in antiviral-untreated patients with chronic hepatitis B. Zhejiang Journal of Preventive Medicine 18: 11-12.
25. Zheng NH, Ji CB, Zhou WH, Ying H, Hu JD, et al. (2007) Detection of naturally emerging HBV YMDD mutation. Chinese Journal of Clinical Hepatology 23: 213-214.
26. Yan MH, Zhang C, Lin Q, Zhou RF, (2003) Detection of YMDD motif mutation in lamivudine-untreated patients with chronic hepatitis B. Chinese Journal of Hepatology 11: 430-431.
27. Wu J, Qian X, (2009) Correlation between hepatitis B virus genotypes and natural mutation of YMDD in Hainan. Journal of Hainan Medical College 15: 714-716.
28. Huang ZM, Huang QW, Qin YQ, He YZ, Qin HJ, et al. (2005) YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 11: 867-870.
29. Qian YQ, Zhao DY, Qian HJ, Lin GC, Huang ZM, (2005) The study of natural HBV YMDD mutation in 125 Zhuang patients with chronic hepatitis in Guangxi province. Journal of Chinese Physician 7: 1551-1552.
30. Qu YY, Wei JJ, Zeng WT, Zhu KL, Ma PQ, (2006) Clinical analysis of HBV YMDD mutation in patients untreated with lamivudine. Journal of Tropical Medicine 6: 791-793.
31. Liu JH, Zeng H, Cao BH, Li XY, Wen FY, et al. (2008) Study on the relationship between lamivudine treatment and YMDD motif mutation. Journal of Chinese Tropical Medicine 8: 1483-1487.
32. Guo HB, Li L, Ye XG, Wang H, (2004) HBV genotyping and detecting of YMDD mutation in patients chronically infected HBV and untreated with antiviral drugs. Journal of Chinese Biotechnology 24: 107-109.
33. Yu J, Huang JM, Zhang YH, Zou DX, Peng LM, (2007) Detection of HBV gene mutation and analyzing for the correlation factors of the mutations. International Medicine and Health Guidance News 13: 63-66.
34. Li CM, Zhang YX, (2003) Detection of lamivudine-resistant HBV YMDD mutation and analyzing the relative factors of YMDD mutation. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 13: 137-139.
35. Zhang XH, Zhang YX, Sun LR, Wen Q, Zhou LQ, et al. (2003) The study of gene chips in detecting YMDD mutations in the region of HBV polymerase. National Medical Journal of China 83: 459-462.
36. Qu JX, Zeng QL, Liu ZG, Xu GH, Fen JH, et al. (2010) Spontaneous HBV YMDD motif mutations in patients with familial clustered chronic HBV infection. World Chinese Journal of Digestology 18: 2604-2607.
37. Qu JX, Liu R, Ren YQ, Fen JH, (2008) Study in naturally occurring HBV YMDD mutations in patients with hepatic cirrhosis. Chinese Journal of Clinical Hepatology 24: 116-117.
38. Pan HQ, Zeng QL, Qu JX, Xu GH, Li YJ, et al. (2010) Epidemiological survey for spontaneous HBV YMDD motif mutation of CHB patients whom under 20 years old and in immune tolerant phase. Medical Information 23: 2094-2095.
39. Zhang Y, Wang PZ, Zhang Y, Li Y, Wei X, et al. (2005) The study of natural HBV YMDD-motif mutation in patients with chronic hepatitis B. Military Medical Journal of South China 19: 13-15.
40. Li L, Mao Q, Huang YP, Wang YM, (2005) Detection of HBV YMDD mutation in patients with chronic hepatitis B and its significance. Acta Academiae Medicinae Militaris Tertiae 27: 167-169.
41. Liu TH, Ling XL, (2004) Detection of YMDD mutation in patients with chronic hepatitis B after lamivudine treatment. Chinese Pharmaceuticals 13: 29.
42. He X, Jiang N, (2007) Analysis on the HBV polymerase gene mutation in lamivudine-resistant patients. Journal of Sichuan University 38: 895-896.
43. Wang YQ, Pu D, (2009) Clinical analysis of natural mutation of YMDD in HBV infection patients. Journal of China Tropical Medicine 9: 652-653.
44. Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, et al. (2004) YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol 74: 361-366.
45. Seta T, Yokosuka O, Imazeki F, Tagawa M, Saisho H, (2000) Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 60: 8-16.
46. Kobayashi S, Ide T, Sata M, (2001) Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 34: 584-586.
47. Heo J, Cho M, Kim HH, Shin YM, Jang HJ, et al. (2004) Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci 19: 541-546.
48. Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM, (2008) Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine. Int J Infec Dis 12: 83-87.
49. Ramezani A, Velayati AA, Roshan MR, Gachkar L, Banifazl M, et al. (2008) Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection. Int J Infec Dis 12: 252-255.
50. Villa E, Lei B, Taliani G, Graziosi A, Critelli R, et al. (2009) Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study. Antivir Ther 14: 1081-1087.
51. Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, et al. (2006) Detection of YMDD motif variants in inactive hepatitis B carriers by Inno-Lipa HBV DR assay. J Gastroenterol and Hepatol 21: 1783-1788.
52. Masaadeh HA, Hayajneh WA, Alqudah EA, (2008) Hepatitis B virus genotypes and lamivudine resistance mutations in Jordan. World J Gastroenterol 14: 7231-7234.
53. Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, et al. (2007) Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-Infected South African patients. J Med Virol 79: 1650-1654.
54. Atkins M, Hunt MC, Brown N, Gray F, Sanathanan L, et al. (1998) Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients. Hepatology 28: 319A.
55. Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, et al. (2004) Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47: 289-309.